Compare Humana Inc (HUM) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Marvell Technology Inc — how do they compare? Humana Inc trades at $373.38 (market cap $46.31B), while Marvell Technology Inc trades at $214.78 (market cap $187.19B). The key difference: Marvell Technology Inc is far larger — about 4× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.92%). Which is the better fit depends on your goals.
| HUM | MRVL | |
|---|---|---|
Market Cap | $46.31B | $187.19B |
Sector | Health | Technology |
52-Week High | $409.42 | $316.43 |
52-Week Low | $163.67 | $62.31 |
Enterprise Value | $53.67B | $188.63B |
Dividend Yield | 0.92% | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
MRVL trades at $218.72, up 3.89% today, with a bullish technical signal from moving averages but neutral oscillators. The stock has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $0.928. Revenue grew to $5.77B in 2025, though net income was negative. Analyst consensus is strongly bullish with an 82% buy rating and a $275.68 price target, implying 26% upside. Recent news highlights AI infrastructure product launches and institutional buying interest.
Outlook is positive driven by AI growth and earnings momentum, but high valuation multiples (P/E 75.16) and geopolitical risks from U.S.-China trade tensions pose challenges. Cash flow trends show improvement, with 2026 net cash flow projected at $3.0B. Investors should weigh strong analyst support against margin pressures and competitive threats in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
